{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:38:23Z","timestamp":1793374703368,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"8075","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2025,8,7]]},"DOI":"10.1038\/s41586-025-09177-7","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T11:02:02Z","timestamp":1750244522000},"page":"214-220","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Targeting de novo purine biosynthesis for tuberculosis treatment"],"prefix":"10.1038","volume":"644","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1066-9026","authenticated-orcid":false,"given":"Dirk A.","family":"Lamprecht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3487-3187","authenticated-orcid":false,"given":"Richard J.","family":"Wall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelies","family":"Leemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Truebody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joke","family":"Sprangers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Fiogbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cadi","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennefer","family":"Wetzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6778-203X","authenticated-orcid":false,"given":"Stijn","family":"Daems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4146-9422","authenticated-orcid":false,"given":"William","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Pillay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Saylock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Daniel","family":"Ricketts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellie","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Huff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsehai","family":"Grell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiming","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Gerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9018-5878","authenticated-orcid":false,"given":"Ann","family":"Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Dallow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam J.","family":"Willcocks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Roubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Sans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandine","family":"Desorme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Chappat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0962-2620","authenticated-orcid":false,"given":"Mariana","family":"Pereira Moraes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Washington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5714-7724","authenticated-orcid":false,"given":"Hope","family":"D\u2019Erasmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavankumar","family":"Sancheti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Everaerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Monshouwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6050-5092","authenticated-orcid":false,"given":"Jorge","family":"Esquivias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6614-8698","authenticated-orcid":false,"given":"Gerald","family":"Larrouy-Maumus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6372-4039","authenticated-orcid":false,"given":"Ruxandra","family":"Draghia Akli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander S.","family":"Pym","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2236-1424","authenticated-orcid":false,"given":"Bree B.","family":"Aldridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1532-146X","authenticated-orcid":false,"given":"Jansy P.","family":"Sarathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen W.","family":"Clancy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Stoops","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5887-8137","authenticated-orcid":false,"given":"Neeraj","family":"Dhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9177-8827","authenticated-orcid":false,"given":"Adrie J. C.","family":"Steyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7438-9141","authenticated-orcid":false,"given":"Clara","family":"Aguilar-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5542-4568","authenticated-orcid":false,"given":"Anil","family":"Koul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"key":"9177_CR1","unstructured":"TB alliance. Get the facts. TB Alliance https:\/\/www.tballiance.org\/why-new-tb-drugs\/global-pandemic (2023)."},{"key":"9177_CR2","unstructured":"World Health Organization. Global tuberculosis report 2023. WHO https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2023 (2023)."},{"key":"9177_CR3","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00272-17","volume":"8","author":"D Bald","year":"2017","unstructured":"Bald, D., Villellas, C., Lu, P. & Koul, A. Targeting energy metabolism in Mycobacterium tuberculosis, a new paradigm in antimycobacterial drug discovery. mBio 8, e00272-17 (2017).","journal-title":"mBio"},{"key":"9177_CR4","doi-asserted-by":"publisher","first-page":"4579","DOI":"10.1016\/j.cell.2021.06.033","volume":"184","author":"B Bosch","year":"2021","unstructured":"Bosch, B. et al. Genome-wide gene expression tuning reveals diverse vulnerabilities of M. tuberculosis. Cell 184, 4579\u20134592.e24 (2021).","journal-title":"Cell"},{"key":"9177_CR5","doi-asserted-by":"publisher","first-page":"e1011663","DOI":"10.1371\/journal.ppat.1011663","volume":"20","author":"AM Block","year":"2024","unstructured":"Block, A. M., Wiegert, P. C., Namugenyi, S. B. & Tischler, A. D. Transposon sequencing reveals metabolic pathways essential for Mycobacterium tuberculosis infection. PLoS Pathog. 20, e1011663 (2024).","journal-title":"PLoS Pathog."},{"key":"9177_CR6","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.02133-16","volume":"8","author":"MA DeJesus","year":"2017","unstructured":"DeJesus, M. A. et al. Comprehensive essentiality analysis of the Mycobacterium tuberculosis genome via saturating transposon mutagenesis. mBio 8, e02133-16 (2017).","journal-title":"mBio"},{"key":"9177_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-75818-y","volume":"14","author":"J Phelan","year":"2024","unstructured":"Phelan, J. et al. An open-access dashboard to interrogate the genetic diversity of Mycobacterium tuberculosis clinical isolates. Sci. Rep. 14, 24792 (2024).","journal-title":"Sci. Rep."},{"key":"9177_CR8","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1007\/s00018-008-8295-8","volume":"65","author":"Y Zhang","year":"2008","unstructured":"Zhang, Y., Morar, M. & Ealick, S. E. Structural biology of the purine biosynthetic pathway. Cell. Mol. Life Sci. 65, 3699\u20133724 (2008).","journal-title":"Cell. Mol. Life Sci."},{"key":"9177_CR9","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","volume":"596","author":"J Jumper","year":"2021","unstructured":"Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583\u2013589 (2021).","journal-title":"Nature"},{"key":"9177_CR10","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.2174\/092986711795029627","volume":"18","author":"RG Ducati","year":"2011","unstructured":"Ducati, R. G., Breda, A., Basso, L. A. & Santos, D. S. Purine salvage pathway in Mycobacterium tuberculosis. Curr. Med. Chem. 18, 1258\u20131275 (2011).","journal-title":"Curr. Med. Chem."},{"key":"9177_CR11","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.3201\/eid1710.100952","volume":"17","author":"K Wallengren","year":"2011","unstructured":"Wallengren, K. et al. Drug-resistant tuberculosis, KwaZulu-Natal, South Africa, 2001\u20132007. Emerg. Infect. Dis. 17, 1913\u20131916 (2011).","journal-title":"Emerg. Infect. Dis."},{"key":"9177_CR12","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2023113490","volume":"42","author":"C Toniolo","year":"2023","unstructured":"Toniolo, C., Dhar, N. & McKinney, J. D. Uptake\u2010independent killing of macrophages by extracellular Mycobacterium tuberculosis aggregates. EMBO J. 42, e113490 (2023).","journal-title":"EMBO J."},{"key":"9177_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4369","volume":"5","author":"A Koul","year":"2014","unstructured":"Koul, A. et al. Delayed bactericidal response of Mycobacterium tuberculosis to bedaquiline involves remodelling of bacterial metabolism. Nat. Commun. 5, 3369 (2014).","journal-title":"Nat. Commun."},{"key":"9177_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3470","volume":"4","author":"I Santi","year":"2013","unstructured":"Santi, I., Dhar, N., Bousbaine, D., Wakamoto, Y. & McKinney, J. D. Single-cell dynamics of the chromosome replication and cell division cycles in mycobacteria. Nat. Commun. 4, 2470 (2013).","journal-title":"Nat. Commun."},{"key":"9177_CR15","doi-asserted-by":"publisher","first-page":"4376","DOI":"10.1073\/pnas.0711159105","volume":"105","author":"AK Pandey","year":"2008","unstructured":"Pandey, A. K. & Sassetti, C. M. Mycobacterial persistence requires the utilization of host cholesterol. Proc. Natl Acad. Sci. USA 105, 4376\u20134380 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"9177_CR16","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.1021\/acsinfecdis.4c00499","volume":"10","author":"P Ashwath","year":"2024","unstructured":"Ashwath, P., Osiecki, P., Weiner, D., Via, L. E. & Sarathy, J. P. Role of DNA double-strand break formation in gyrase inhibitor-mediated killing of nonreplicating persistent Mycobacterium tuberculosis in caseum. ACS Infect. Dis. 10, 3631\u20133639 (2024).","journal-title":"ACS Infect. Dis."},{"key":"9177_CR17","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02266-17","volume":"62","author":"JP Sarathy","year":"2018","unstructured":"Sarathy, J. P. et al. Extreme drug tolerance of Mycobacterium tuberculosis in caseum. Antimicrob. Agents Chemother. 62, e02266-17 (2018).","journal-title":"Antimicrob. Agents Chemother."},{"key":"9177_CR18","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00597-23","volume":"67","author":"ME Ramey","year":"2023","unstructured":"Ramey, M. E. et al. Drug distribution and efficacy of the DprE1 inhibitor BTZ-043 in the C3HeB\/FeJ mouse tuberculosis model. Antimicrob. Agents Chemother. 67, e0059723 (2023).","journal-title":"Antimicrob. Agents Chemother."},{"key":"9177_CR19","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00159-19","volume":"33","author":"JP Sarathy","year":"2020","unstructured":"Sarathy, J. P. & Dartois, V. Caseum: a niche for Mycobacterium tuberculosis drug-tolerant persisters. Clin. Microbiol. Rev. 33, e00159-19 (2020).","journal-title":"Clin. Microbiol. Rev."},{"key":"9177_CR20","doi-asserted-by":"publisher","first-page":"e1002093","DOI":"10.1371\/journal.ppat.1002093","volume":"7","author":"J Daniel","year":"2011","unstructured":"Daniel, J., Maamar, H., Deb, C., Sirakova, T. D. & Kolattukudy, P. E. Mycobacterium tuberculosis uses host triacylglycerol to accumulate lipid droplets and acquires a dormancy-like phenotype in lipid-loaded macrophages. PLoS Pathog. 7, e1002093 (2011).","journal-title":"PLoS Pathog."},{"key":"9177_CR21","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2018025649","volume":"36","author":"K Chaudhary","year":"2019","unstructured":"Chaudhary, K., Patel, M. M. & Mehta, P. J. Long-acting injectables: current perspectives and future promise. Crit. Rev. Ther. Drug Carrier Syst. 36, 137\u2013181 (2019).","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"9177_CR22","unstructured":"World Health Organization. New treatment for drug-resistant tuberculosis. WHO https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2023\/featured-topics\/new-treatment-tb (2023)."},{"key":"9177_CR23","doi-asserted-by":"publisher","first-page":"567","DOI":"10.5588\/ijtld.22.0632","volume":"27","author":"D Vengurlekar","year":"2023","unstructured":"Vengurlekar, D. et al. Linezolid resistance in patients with drug-resistant TB. Int. J. Tuberc. Lung Dis. 27, 567\u2013569 (2023).","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"9177_CR24","doi-asserted-by":"publisher","first-page":"e947","DOI":"10.1093\/cid\/ciac485","volume":"76","author":"J Eimer","year":"2022","unstructured":"Eimer, J. et al. Association between increased linezolid plasma concentrations and the development of severe toxicity in multidrug-resistant tuberculosis treatment. Clin. Infect. Dis. 76, e947\u2013e956 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"9177_CR25","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1093\/jac\/dkac019","volume":"77","author":"S Wasserman","year":"2022","unstructured":"Wasserman, S. et al. Linezolid toxicity in patients with drug-resistant tuberculosis: a prospective cohort study. J. Antimicrob. Chemother. 77, 1146\u20131154 (2022).","journal-title":"J. Antimicrob. Chemother."},{"key":"9177_CR26","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.1701881","volume":"3","author":"M Cokol","year":"2017","unstructured":"Cokol, M., Kuru, N., Bicak, E., Larkins-Ford, J. & Aldridge, B. B. Efficient measurement and factorization of high-order drug interactions in Mycobacterium tuberculosis. Sci. Adv. 3, e1701881 (2017).","journal-title":"Sci. Adv."},{"key":"9177_CR27","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1126\/science.1106753","volume":"307","author":"K Andries","year":"2005","unstructured":"Andries, K. et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307, 223\u2013227 (2005).","journal-title":"Science"},{"key":"9177_CR28","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1038\/nm.3262","volume":"19","author":"K Pethe","year":"2013","unstructured":"Pethe, K. et al. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat. Med. 19, 1157\u20131160 (2013).","journal-title":"Nat. Med."},{"key":"9177_CR29","unstructured":"World Health Organization. Target regimen profiles for tuberculosis treatment, 2023 update. WHO https:\/\/www.who.int\/publications\/i\/item\/9789240081512 (2023)."},{"key":"9177_CR30","unstructured":"Janssen Cilag International. A single ascending dose, single-centre study, to assess pharmacokinetics, safety and tolerability of a single intramuscular dose of bedaquiline long-acting injection formulation in healthy participants (EU Clinical Trial 2023-508810-41-00). EU Clinical Trials https:\/\/euclinicaltrials.eu\/search-for-clinical-trials\/?lang=en&EUCT=2023-508810-41-00 (2024)."},{"key":"9177_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/srep38986","volume":"6","author":"JA Cox","year":"2016","unstructured":"Cox, J. A. et al. Novel inhibitors of Mycobacterium tuberculosis GuaB2 identified by a target based high-throughput phenotypic screen. Sci. Rep. 6, 38986 (2016).","journal-title":"Sci. Rep."},{"key":"9177_CR32","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1021\/acsinfecdis.6b00102","volume":"3","author":"V Singh","year":"2017","unstructured":"Singh, V. et al. The inosine monophosphate dehydrogenase, GuaB2, is a vulnerable new bactericidal drug target for tuberculosis. ACS Infect. Dis. 3, 5\u201317 (2017).","journal-title":"ACS Infect. Dis."},{"key":"9177_CR33","doi-asserted-by":"publisher","first-page":"e33886","DOI":"10.1371\/journal.pone.0033886","volume":"7","author":"V Usha","year":"2012","unstructured":"Usha, V., Hobrath, J. V., Gurcha, S. S., Reynolds, R. C. & Besra, G. S. Identification of novel Mt-Guab2 inhibitor series active against M. tuberculosis. PLoS ONE 7, e33886 (2012).","journal-title":"PLoS ONE"},{"key":"9177_CR34","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1021\/acsinfecdis.6b00103","volume":"3","author":"Y Park","year":"2017","unstructured":"Park, Y. et al. Essential but not vulnerable: indazole sulfonamides targeting inosine monophosphate dehydrogenase as potential leads against Mycobacterium tuberculosis. ACS Infect. Dis. 3, 18\u201333 (2017).","journal-title":"ACS Infect. Dis."},{"key":"9177_CR35","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/s41586-019-1735-9","volume":"575","author":"S Ahmad","year":"2019","unstructured":"Ahmad, S. et al. An interbacterial toxin inhibits target cell growth by synthesizing (p)ppApp. Nature 575, 674\u2013678 (2019).","journal-title":"Nature"},{"key":"9177_CR36","doi-asserted-by":"publisher","first-page":"11061","DOI":"10.1021\/bi9714114","volume":"36","author":"JM Krahn","year":"1997","unstructured":"Krahn, J. M. et al. Coupled formation of an amidotransferase interdomain ammonia channel and a phosphoribosyltransferase active site. Biochemistry 36, 11061\u201311068 (1997).","journal-title":"Biochemistry"},{"key":"9177_CR37","doi-asserted-by":"publisher","first-page":"D439","DOI":"10.1093\/nar\/gkab1061","volume":"50","author":"M Varadi","year":"2021","unstructured":"Varadi, M. et al. AlphaFold Protein Structure Database: massively expanding the structural coverage of protein-sequence space with high-accuracy models. Nucleic Acids Res. 50, D439\u2013D444 (2021).","journal-title":"Nucleic Acids Res."},{"key":"9177_CR38","unstructured":"Chemical Computing Group. Molecular Operating Environment (MOE), 2022.02. Chemical Computing Group https:\/\/www.chemcomp.com\/en\/Research.htm (2024)."},{"key":"9177_CR39","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/j.1747-0285.2007.00483.x","volume":"69","author":"T Halgren","year":"2007","unstructured":"Halgren, T. New method for fast and accurate binding-site identification and analysis. Chem. Biol. Drug Des. 69, 146\u2013148 (2007).","journal-title":"Chem. Biol. Drug Des."},{"key":"9177_CR40","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1021\/ci800324m","volume":"49","author":"TA Halgren","year":"2009","unstructured":"Halgren, T. A. Identifying and characterizing binding sites and assessing druggability. J. Chem. Inf. Model. 49, 377\u2013389 (2009).","journal-title":"J. Chem. Inf. Model."},{"key":"9177_CR41","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1021\/acs.jctc.3c00839","volume":"20","author":"D Coskun","year":"2024","unstructured":"Coskun, D. et al. Using AlphaFold and experimental structures for the prediction of the structure and binding affinities of GPCR complexes via induced fit docking and free energy perturbation. J. Chem. Theory Comput. 20, 477\u2013489 (2024).","journal-title":"J. Chem. Theory Comput."},{"key":"9177_CR42","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1021\/acs.jctc.1c00136","volume":"17","author":"EB Miller","year":"2021","unstructured":"Miller, E. B. et al. Reliable and accurate solution to the induced fit docking problem for protein-ligand binding. J. Chem. Theory Comput. 17, 2630\u20132639 (2021).","journal-title":"J. Chem. Theory Comput."},{"key":"9177_CR43","doi-asserted-by":"publisher","first-page":"5710","DOI":"10.1021\/acs.jctc.2c00371","volume":"18","author":"T Xu","year":"2022","unstructured":"Xu, T. et al. Induced-fit docking enables accurate free energy perturbation calculations in homology models. J. Chem. Theory Comput. 18, 5710\u20135724 (2022).","journal-title":"J. Chem. Theory Comput."},{"key":"9177_CR44","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/nprot.2008.73","volume":"3","author":"TD Schmittgen","year":"2008","unstructured":"Schmittgen, T. D. & Livak, K. J. Analyzing real-time PCR data by the comparative CT method. Nat. Protoc. 3, 1101\u20131108 (2008).","journal-title":"Nat. Protoc."},{"key":"9177_CR45","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.pep.2009.01.002","volume":"65","author":"DJ Wasilko","year":"2009","unstructured":"Wasilko, D. J. et al. The titerless infected-cells preservation and scale-up (TIPS) method for large-scale production of NO-sensitive human soluble guanylate cyclase (sGC) from insect cells infected with recombinant baculovirus. Protein Exp. Purif. 65, 122\u2013132 (2009).","journal-title":"Protein Exp. Purif."},{"key":"9177_CR46","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/978-1-4939-2450-9_14","volume":"1285","author":"N Dhar","year":"2015","unstructured":"Dhar, N. & Manina, G. Single-cell analysis of mycobacteria using microfluidics and time-lapse microscopy. Methods Mol. Biol. 1285, 241\u2013256 (2015).","journal-title":"Methods Mol. Biol."},{"key":"9177_CR47","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676\u2013682 (2012).","journal-title":"Nat. Methods"},{"key":"9177_CR48","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.tube.2004.02.003","volume":"84","author":"MI Voskuil","year":"2004","unstructured":"Voskuil, M. I., Visconti, K. C. & Schoolnik, G. K. Mycobacterium tuberculosis gene expression during adaptation to stationary phase and low-oxygen dormancy. Tuberculosis 84, 218\u2013227 (2004).","journal-title":"Tuberculosis"},{"key":"9177_CR49","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1021\/acsomega.0c05589","volume":"6","author":"PC Ray","year":"2021","unstructured":"Ray, P. C. et al. Spirocycle MmpL3 inhibitors with improved hERG and cytotoxicity profiles as inhibitors of Mycobacterium tuberculosis growth. ACS Omega 6, 2284\u20132311 (2021).","journal-title":"ACS Omega"},{"key":"9177_CR50","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1021\/acsinfecdis.0c00252","volume":"6","author":"JN Akester","year":"2020","unstructured":"Akester, J. N. et al. Synthesis, structure-activity relationship, and mechanistic studies of aminoquinazolinones displaying antimycobacterial activity. ACS Infect. Dis. 6, 1951\u20131964 (2020).","journal-title":"ACS Infect. Dis."},{"key":"9177_CR51","doi-asserted-by":"publisher","first-page":"e0101023","DOI":"10.1128\/aac.01010-23","volume":"68","author":"MA Lyons","year":"2024","unstructured":"Lyons, M. A. et al. Use of multiple pharmacodynamic measures to deconstruct the Nix-TB regimen in a short-course murine model of tuberculosis. Antimicrob. Agents Chemother. 68, e0101023 (2024).","journal-title":"Antimicrob. Agents Chemother."},{"key":"9177_CR52","doi-asserted-by":"publisher","first-page":"100737","DOI":"10.1016\/j.xcrm.2022.100737","volume":"3","author":"J Larkins-Ford","year":"2022","unstructured":"Larkins-Ford, J., Degefu, Y. N., Van, N., Sokolov, A. & Aldridge, B. B. Design principles to assemble drug combinations for effective tuberculosis therapy using interpretable pairwise drug response measurements. Cell Rep. Med. 3, 100737 (2022).","journal-title":"Cell Rep. Med."},{"key":"9177_CR53","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.cels.2021.08.004","volume":"12","author":"J Larkins-Ford","year":"2021","unstructured":"Larkins-Ford, J. et al. Systematic measurement of combination-drug landscapes to predict in vivo treatment outcomes for tuberculosis. Cell Syst. 12, 1046\u20131063.e7 (2021).","journal-title":"Cell Syst."},{"key":"9177_CR54","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S2213-2600(19)30366-2","volume":"7","author":"CD Tweed","year":"2019","unstructured":"Tweed, C. D. et al. Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial. Lancet Respir. Med. 7, 1048\u20131058 (2019).","journal-title":"Lancet Respir. Med."},{"key":"9177_CR55","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/S1473-3099(24)00223-8","volume":"24","author":"M Cevik","year":"2024","unstructured":"Cevik, M. et al. Bedaquiline\u2013pretomanid\u2013moxifloxacin\u2013pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial. Lancet Infect. Dis. 24, 1003\u20131014 (2024).","journal-title":"Lancet Infect. Dis."}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-09177-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-09177-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-09177-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T22:16:55Z","timestamp":1757197015000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-09177-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":55,"journal-issue":{"issue":"8075","published-print":{"date-parts":[[2025,8,7]]}},"alternative-id":["9177"],"URL":"https:\/\/doi.org\/10.1038\/s41586-025-09177-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4913610\/v1","asserted-by":"object"}]},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,18]]},"assertion":[{"value":"14 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.A.L., A.L., J.S., P.F., J.W., S.D., S.\u00a0Saylock, M.D.R., A.H., T.G., A.V., K.W.C., P.S., M.E., M.M., J.E., R.D.A., H.F., A.S.P., B.S., C.A.-P., P.J. and A.K. were or are all full-time employees of Janssen Pharmaceutica, a Johnson & Johnson company, and\/or potential stockholders of Johnson & Johnson. J.S. and P.F. were or are employees of Charles River Laboratories, a contract research organization. A.R., C.R., N.C. and S.\u00a0Sans were or are all full-time employees of Evotec. R.J.W., C.D., W.P., E.D., S.L., M.G., J.D., S.J.W., G.L.-M., N.D. and A.K. received funding from Janssen Pharmaceutica to perform contract research. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}